366 related articles for article (PubMed ID: 29425455)
1. Optimal HTS Fingerprint Definitions by Using a Desirability Function and a Genetic Algorithm.
Cortes Cabrera A; Petrone PM
J Chem Inf Model; 2018 Mar; 58(3):641-646. PubMed ID: 29425455
[TBL] [Abstract][Full Text] [Related]
2. Using information from historical high-throughput screens to predict active compounds.
Riniker S; Wang Y; Jenkins JL; Landrum GA
J Chem Inf Model; 2014 Jul; 54(7):1880-91. PubMed ID: 24933016
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Iterative Screening with Stepwise Compound Selection Based on Novartis In-house HTS Data.
Paricharak S; IJzerman AP; Bender A; Nigsch F
ACS Chem Biol; 2016 May; 11(5):1255-64. PubMed ID: 26878899
[TBL] [Abstract][Full Text] [Related]
4. Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files.
Bell AS; Bradley J; Everett JR; Loesel J; McLoughlin D; Mills J; Peakman MC; Sharp RE; Williams C; Zhu H
Mol Divers; 2016 Nov; 20(4):789-803. PubMed ID: 27631533
[TBL] [Abstract][Full Text] [Related]
5. Average Information Content Maximization--A New Approach for Fingerprint Hybridization and Reduction.
Śmieja M; Warszycki D
PLoS One; 2016; 11(1):e0146666. PubMed ID: 26784447
[TBL] [Abstract][Full Text] [Related]
6. Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes.
Wassermann AM; Kutchukian PS; Lounkine E; Luethi T; Hamon J; Bocker MT; Malik HA; Cowan-Jacob SW; Glick M
J Med Chem; 2013 Nov; 56(21):8879-91. PubMed ID: 24117015
[TBL] [Abstract][Full Text] [Related]
7. Biodiversity of small molecules--a new perspective in screening set selection.
Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
[TBL] [Abstract][Full Text] [Related]
8. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
[TBL] [Abstract][Full Text] [Related]
9. AI is a viable alternative to high throughput screening: a 318-target study.
Atomwise AIMS Program
Sci Rep; 2024 Apr; 14(1):7526. PubMed ID: 38565852
[TBL] [Abstract][Full Text] [Related]
10. A Multimodal Data Analysis Approach for Targeted Drug Discovery Involving Topological Data Analysis (TDA).
Alagappan M; Jiang D; Denko N; Koong AC
Adv Exp Med Biol; 2016; 899():253-68. PubMed ID: 27325272
[TBL] [Abstract][Full Text] [Related]
11. Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening.
Paricharak S; Méndez-Lucio O; Chavan Ravindranath A; Bender A; IJzerman AP; van Westen GJP
Brief Bioinform; 2018 Mar; 19(2):277-285. PubMed ID: 27789427
[TBL] [Abstract][Full Text] [Related]
12. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
Roy A; McDonald PR; Sittampalam S; Chaguturu R
Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
[TBL] [Abstract][Full Text] [Related]
13. Scopy: an integrated negative design python library for desirable HTS/VS database design.
Yang ZY; Yang ZJ; Lu AP; Hou TJ; Cao DS
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32892221
[TBL] [Abstract][Full Text] [Related]
14. Diversity selection of compounds based on 'protein affinity fingerprints' improves sampling of bioactive chemical space.
Nguyen HP; Koutsoukas A; Mohd Fauzi F; Drakakis G; Maciejewski M; Glen RC; Bender A
Chem Biol Drug Des; 2013 Sep; 82(3):252-66. PubMed ID: 23647865
[TBL] [Abstract][Full Text] [Related]
15. Screening Library Design.
Ashenden SK
Methods Enzymol; 2018; 610():73-96. PubMed ID: 30390806
[TBL] [Abstract][Full Text] [Related]
16. Cheminformatics approaches to analyze diversity in compound screening libraries.
Akella LB; DeCaprio D
Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001
[TBL] [Abstract][Full Text] [Related]
17. The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs.
Fan F; Toledo Warshaviak D; Hamadeh HK; Dunn RT
PLoS One; 2019; 14(1):e0204378. PubMed ID: 30605479
[TBL] [Abstract][Full Text] [Related]
18. Nuisance Compounds, PAINS Filters, and Dark Chemical Matter in the GSK HTS Collection.
Chakravorty SJ; Chan J; Greenwood MN; Popa-Burke I; Remlinger KS; Pickett SD; Green DVS; Fillmore MC; Dean TW; Luengo JI; Macarrón R
SLAS Discov; 2018 Jul; 23(6):532-545. PubMed ID: 29699447
[TBL] [Abstract][Full Text] [Related]
19. HTS navigator: freely accessible cheminformatics software for analyzing high-throughput screening data.
Fourches D; Sassano MF; Roth BL; Tropsha A
Bioinformatics; 2014 Feb; 30(4):588-9. PubMed ID: 24376084
[TBL] [Abstract][Full Text] [Related]
20. High-Throughput Screening and Triage Assays Identify Small Molecules Targeting c-MYC in Cancer Cells.
Kallal LA; Waszkiewicz A; Jaworski JP; Della Pietra A; Berrodin T; Brady P; Jurewicz AJ; Zeng X; Payne L; Medina JR; Doepner-Buser C; Mangatt B
SLAS Discov; 2021 Feb; 26(2):216-229. PubMed ID: 33482073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
